According to Ruikang Pharmaceutical's announcement, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for two consecutive trading days on December 3 and 4, 2025, which is an abnormal fluctuation. The company carried out its own inspection and verification. There was no need to correct or supplement the information disclosed in the early stages; no major information was disclosed in media reports; production and operation were normal; there were no important matters that should be disclosed; no cases where controlling shareholders, etc. did not trade the company's shares during the period of abnormal fluctuations; nor were there any violations of fair information disclosure regulations. The company reminds investors to invest rationally and pay attention to risks.

According to Ruikang Pharmaceutical's announcement, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for two consecutive trading days on December 3 and 4, 2025, which is an abnormal fluctuation. The company carried out its own inspection and verification. There was no need to correct or supplement the information disclosed in the early stages; no major information was disclosed in media reports; production and operation were normal; there were no important matters that should be disclosed; no cases where controlling shareholders, etc. did not trade the company's shares during the period of abnormal fluctuations; nor were there any violations of fair information disclosure regulations. The company reminds investors to invest rationally and pay attention to risks.